Beyond glycaemic control: Discovering oral antidiabetics that protect against T2DM-related complications
26 Nov 2019
It is estimated 3.3 million Malaysians are diabetic, with another 1.7 million people living with undiagnosed diabetes
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
Related MIMS Drugs